Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells

BOSTON–(BUSINESS WIRE)–lt;a href=”” target=”_blank”gt;$GMDAlt;/agt;–Gamida
Cell Ltd.
(Nasdaq: GMDA), a leading cellular and immune therapeutics
company, today announced an agreement with Editas Medicine, Inc., a
leading genome editing company, to evaluate the potential use of Editas
Medicine’s CRISPR technology to edit NAM-NK cells, which are natural
killer cells that have been expanded using Gamida Cell’s proprietary
nicotinamide-based, or NAM, technology. Through this agreement, the
companies aim to discover optimized NAM-NK cells that could be used to
improve the treatment of hematologic malignancies (blood cancers) and
solid tumors.

“We are encouraged by the early data generated in the Phase 1 study of
NAM-NK as an investigational therapy for patients with non-Hodgkin
lymphoma and multiple myeloma, and we are pleased to have the
opportunity to accelerate and broaden our NAM-NK research efforts
through this agreement,” stated Julian Adams, Ph.D., chief executive
officer of Gamida Cell. “By leveraging the collective expertise of the
Gamida Cell and Editas Medicine teams, we hope to enhance the efficacy
of NAM-NK cells through CRISPR editing and potentially bring
life-changing immunotherapy treatments to patients.”

“Natural killer cells are increasingly recognized as a potential
breakthrough approach to treating various cancers. This agreement with
Gamida Cell enables us to combine our industry-leading genome editing
platform with Gamida Cell’s proprietary NAM-NK cells in an effort to
develop best-in-class cellular medicines,” said Charles Albright, Ph.D.,
chief scientific officer of Editas Medicine.

Under the terms of the agreement, Gamida Cell and Editas Medicine will
engage in joint research to evaluate unnamed targets by combining Gamida
Cell’s proprietary NAM-based cell expansion technology with Editas
Medicine’s CRISPR technology. The research initiative is focused on
exploring the potential to edit NAM-NK cells to further optimize their
tumor-killing properties, and compare the function of the edited and
unedited cells in inducing NK cell tumor clearance.

About NAM-NK
Gamida Cell applied the capabilities of its
NAM-based cell expansion technology to highly functional NK cells to
develop NAM-NK, an innate immunotherapy for the treatment of hematologic
and solid tumors in combination with standard-of-care antibody
therapies. NAM-NK addresses key limitations of NK cells by increasing
the cytotoxicity and in vivo retention and proliferation in the
bone marrow and lymphoid organs of NK cells expanded in culture. NAM-NK
is in Phase 1 development through an investigator-sponsored study in
patients with refractory non-Hodgkin lymphoma and multiple myeloma.1

NAM-NK is an investigational therapy, and its safety and efficacy has
not been evaluated by the U.S. Food and Drug Administration or any other
health authority.

About Gamida Cell
Gamida Cell is a clinical stage
biopharmaceutical company leveraging its proprietary technology to
develop cell therapies that are designed to cure cancer and rare,
serious hematologic diseases. The company is applying its nicotinamide-,
or NAM-, based cell expansion technology to develop a pipeline of
products designed to address the limitations of cell therapies.

Cautionary Note Regarding Forward Looking
This press release
contains forward-looking statements as that term is defined in the
Private Securities Litigation Reform Act of 1995, including with respect
to the prospective use of CRISPR technology in combination with NAM-NK
cells, which statements are subject to a number of risks, uncertainties
and assumptions, including, but not limited to clinical or technological
developments. In light of these risks and uncertainties, and other risks
and uncertainties that are described in the Risk Factors section of our
Registration Statement on Form F-1 filed with the SEC on September 28,
2018, and other filings that Gamida Cell makes with the SEC from time to
time (which are available at,
the events and circumstances discussed in such forward-looking
statements may not occur, and Gamida Cell’s actual results could differ
materially and adversely from those anticipated or implied thereby. Any
forward-looking statements speak only as of the date of this press
release and are based on information available to Gamida Cell as of the
date of this release.

1 identifier NCT03019666.


Jaren Irene Madden

Gibbs (media)

error: Content is protected !!